Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.
Curtis NJ, Mooney L, Hopcroft L, Michopoulos F, Whalley N, Zhong H, Murray C, Logie A, Revill M, Byth KF, Benjamin AD, Firth MA, Green S, Smith PD, Critchlow SE.
Curtis NJ, et al. Among authors: firth ma.
Oncotarget. 2017 May 25;8(41):69219-69236. doi: 10.18632/oncotarget.18215. eCollection 2017 Sep 19.
Oncotarget. 2017.
PMID: 29050199
Free PMC article.